Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk: Results from the EPIC cohort

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk : Results from the EPIC cohort. / Cramer, Daniel W.; Fichorova, Raina N.; Terry, Kathryn L.; Yamamoto, Hidemi; Vitonis, Allison F.; Ardanaz, Eva; Aune, Dagfinn; Boeing, Heiner; Brandstedt, Jenny; Boutron-Ruault, Marie Christine; Chirlaque, Maria Dolores; Dorronsoro, Miren; Dossus, Laure; Duell, Eric J.; Gram, Inger T.; Gunter, Marc; Hansen, Louise; Idahl, Annika; Johnson, Theron; Khaw, Kay Tee; Krogh, Vittorio; Kvaskoff, Marina; Mattiello, Amalia; Matullo, Giuseppe; Merritt, Melissa A.; Nodin, Bjorn; Orfanos, Philippos; Onland-Moret, N. Charlotte; Palli, Domenico; Peppa, Eleni; Quiros, J. Ramon; Sanchez-Perez, Maria Jose; Severi, Gianluca; Tjønneland, Anne; Travis, Ruth C.; Trichopoulou, Antonia; Tumino, Rosario; Weiderpass, Elisabete; Fortner, Renee T.; Kaaks, Rudolf.

I: Cancer Epidemiology Biomarkers and Prevention, Vol. 27, Nr. 7, 01.07.2018, s. 790-804.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Cramer, DW, Fichorova, RN, Terry, KL, Yamamoto, H, Vitonis, AF, Ardanaz, E, Aune, D, Boeing, H, Brandstedt, J, Boutron-Ruault, MC, Chirlaque, MD, Dorronsoro, M, Dossus, L, Duell, EJ, Gram, IT, Gunter, M, Hansen, L, Idahl, A, Johnson, T, Khaw, KT, Krogh, V, Kvaskoff, M, Mattiello, A, Matullo, G, Merritt, MA, Nodin, B, Orfanos, P, Onland-Moret, NC, Palli, D, Peppa, E, Quiros, JR, Sanchez-Perez, MJ, Severi, G, Tjønneland, A, Travis, RC, Trichopoulou, A, Tumino, R, Weiderpass, E, Fortner, RT & Kaaks, R 2018, 'Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk: Results from the EPIC cohort', Cancer Epidemiology Biomarkers and Prevention, vol. 27, nr. 7, s. 790-804. https://doi.org/10.1158/1055-9965.EPI-17-0744

APA

Cramer, D. W., Fichorova, R. N., Terry, K. L., Yamamoto, H., Vitonis, A. F., Ardanaz, E., ... Kaaks, R. (2018). Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk: Results from the EPIC cohort. Cancer Epidemiology Biomarkers and Prevention, 27(7), 790-804. https://doi.org/10.1158/1055-9965.EPI-17-0744

CBE

Cramer DW, Fichorova RN, Terry KL, Yamamoto H, Vitonis AF, Ardanaz E, Aune D, Boeing H, Brandstedt J, Boutron-Ruault MC, Chirlaque MD, Dorronsoro M, Dossus L, Duell EJ, Gram IT, Gunter M, Hansen L, Idahl A, Johnson T, Khaw KT, Krogh V, Kvaskoff M, Mattiello A, Matullo G, Merritt MA, Nodin B, Orfanos P, Onland-Moret NC, Palli D, Peppa E, Quiros JR, Sanchez-Perez MJ, Severi G, Tjønneland A, Travis RC, Trichopoulou A, Tumino R, Weiderpass E, Fortner RT, Kaaks R. 2018. Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk: Results from the EPIC cohort. Cancer Epidemiology Biomarkers and Prevention. 27(7):790-804. https://doi.org/10.1158/1055-9965.EPI-17-0744

MLA

Vancouver

Author

Cramer, Daniel W. ; Fichorova, Raina N. ; Terry, Kathryn L. ; Yamamoto, Hidemi ; Vitonis, Allison F. ; Ardanaz, Eva ; Aune, Dagfinn ; Boeing, Heiner ; Brandstedt, Jenny ; Boutron-Ruault, Marie Christine ; Chirlaque, Maria Dolores ; Dorronsoro, Miren ; Dossus, Laure ; Duell, Eric J. ; Gram, Inger T. ; Gunter, Marc ; Hansen, Louise ; Idahl, Annika ; Johnson, Theron ; Khaw, Kay Tee ; Krogh, Vittorio ; Kvaskoff, Marina ; Mattiello, Amalia ; Matullo, Giuseppe ; Merritt, Melissa A. ; Nodin, Bjorn ; Orfanos, Philippos ; Onland-Moret, N. Charlotte ; Palli, Domenico ; Peppa, Eleni ; Quiros, J. Ramon ; Sanchez-Perez, Maria Jose ; Severi, Gianluca ; Tjønneland, Anne ; Travis, Ruth C. ; Trichopoulou, Antonia ; Tumino, Rosario ; Weiderpass, Elisabete ; Fortner, Renee T. ; Kaaks, Rudolf. / Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk : Results from the EPIC cohort. I: Cancer Epidemiology Biomarkers and Prevention. 2018 ; Vol. 27, Nr. 7. s. 790-804.

RIS

TY - JOUR

T1 - Anti-CA15.3 and Anti-CA125 Antibodies and ovarian cancer risk

T2 - Results from the EPIC cohort

AU - Cramer, Daniel W.

AU - Fichorova, Raina N.

AU - Terry, Kathryn L.

AU - Yamamoto, Hidemi

AU - Vitonis, Allison F.

AU - Ardanaz, Eva

AU - Aune, Dagfinn

AU - Boeing, Heiner

AU - Brandstedt, Jenny

AU - Boutron-Ruault, Marie Christine

AU - Chirlaque, Maria Dolores

AU - Dorronsoro, Miren

AU - Dossus, Laure

AU - Duell, Eric J.

AU - Gram, Inger T.

AU - Gunter, Marc

AU - Hansen, Louise

AU - Idahl, Annika

AU - Johnson, Theron

AU - Khaw, Kay Tee

AU - Krogh, Vittorio

AU - Kvaskoff, Marina

AU - Mattiello, Amalia

AU - Matullo, Giuseppe

AU - Merritt, Melissa A.

AU - Nodin, Bjorn

AU - Orfanos, Philippos

AU - Onland-Moret, N. Charlotte

AU - Palli, Domenico

AU - Peppa, Eleni

AU - Quiros, J. Ramon

AU - Sanchez-Perez, Maria Jose

AU - Severi, Gianluca

AU - Tjønneland, Anne

AU - Travis, Ruth C.

AU - Trichopoulou, Antonia

AU - Tumino, Rosario

AU - Weiderpass, Elisabete

AU - Fortner, Renee T.

AU - Kaaks, Rudolf

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both. Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types. Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC.

AB - Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression. Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both. Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types. Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC.

UR - http://www.scopus.com/inward/record.url?scp=85049634585&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-17-0744

DO - 10.1158/1055-9965.EPI-17-0744

M3 - Article

VL - 27

SP - 790

EP - 804

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1538-7755

IS - 7

ER -